NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
24/05/2022
Voltar para busca
Dado oficial do USPTO
ACTIMED THERAPEUTICS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
ACTIMED THERAPEUTICS
ST13
US500000088049205Classe
5, 44
Pedido
88049205
Registro
6734037
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
24/05/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 44
Data de depósito
23/07/2018
Data de registro
24/05/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
24/05/2022
Última transação
24/05/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
Berkshire, GB
Examinador
CORWIN, KEVIN
Unidade examinadora
M30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Actimed Therapeutics Limited
Representantes
M. Scott Alprin Alprin Law Offices, P.C.
Classificação técnica
Classes Nice
Classe 5Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticalmedical and therapeutic substances and preparations; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases; pharmaceuticalmedical and therapeutic substances and preparations for countering adverse effects of cancersof severe or chronic illnesses and diseases; pharmaceuticalmedical and therapeutic substances and preparations for treatment and management of physical function; pharmaceuticalmedical and therapeutic substances and preparations for treatment and prevention of muscle wasting; pharmaceuticalmedical and therapeutic substances and preparations for treatment and management of patient tolerance of therapiesin particular anticancer therapy; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of cachexiain particular cancer cachexia; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of the side effects of medical treatmentsin particular of cancer treatments; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the lung; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the kidney; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the heart; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the liver; pharmaceuticalmedical and therapeutic substances and preparations for the treatment and management of severe or chronic illnesses and diseases of the brain; pharmaceuticalmedical and therapeutic substances and preparations for countering adverse effects of chronic heart failure; pharmaceuticalmedical and therapeutic substances and preparations for countering adverse effects of chronic renal failure; pharmaceuticalmedical and therapeutic substances and preparations for countering adverse effects of chronic liver failure; pharmaceuticalmedical and therapeutic substances and preparations for countering adverse effects of chronic obstructive pulmonary disease; pharmaceuticalmedical and therapeutic substances and preparations for countering adverse effects of neurological-muscular disorders
Classe 44
Informationadvisory and consultancy services relating to medicine and healthcare; medical and surgical diagnosis and treatment services; medical analysis and reporting services relating to the treatment of patients; assessment and monitoring of patients; preparation of data and reports relating to medicine and healthcare; medical testing services relating to the diagnosis and treatment of illnessesdiseases and medical conditions; providing information relating to the managementpreparation and dispensing of medications; medicalhealthdentistryveterinary and pharmaceutical services; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to severe or chronic illnesses and diseases; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to countering adverse effects of cancersof severe or chronic illnesses and diseases; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to physical function and muscle wasting; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to patient tolerance of therapiesin particular anticancer therapy; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of cachexiain particular cancer cachexia; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of the side effects of medical treatmentsin particular of cancer treatments; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the lung; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the kidney; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the heart; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the liver; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to the treatment and management of severe or chronic illnesses and diseases of the brain; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to countering adverse effects of chronic heart failure; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to countering adverse effects of chronic renal failure; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to countering adverse effects of chronic liver failure; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to countering adverse effects of chronic obstructive pulmonary disease; medical diagnosistreatmenttestinganalysisreportingassessment and monitoring services relating to countering adverse effects of neurological-muscular disorders; advisoryinformation and consultancy services relating to all the aforesaid services
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
24/05/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
08/03/2022
PUBO
PUBLISHED FOR OPPOSITION
08/03/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
16/02/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/01/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
27/01/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
27/01/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
27/01/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
27/01/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/12/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/12/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
09/12/2021
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
01/10/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
01/10/2021
CNSI
SUSPENSION INQUIRY WRITTEN
01/10/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
24/09/2021
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
02/03/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
06/08/2020
GNSL
LETTER OF SUSPENSION E-MAILED
06/08/2020
CNSL
SUSPENSION LETTER WRITTEN
06/08/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
17/07/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/07/2020
ALIE
ASSIGNED TO LIE
12/07/2020
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
30/06/2020
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
27/01/2020
GNSI
INQUIRY TO SUSPENSION E-MAILED
27/01/2020
CNSI
SUSPENSION INQUIRY WRITTEN
27/01/2020
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
02/07/2019
GNSL
LETTER OF SUSPENSION E-MAILED
02/07/2019
CNSL
SUSPENSION LETTER WRITTEN
02/07/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
29/05/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
28/05/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
28/05/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
27/11/2018
GNRT
NON-FINAL ACTION E-MAILED
27/11/2018
CNRT
NON-FINAL ACTION WRITTEN
27/11/2018
DOCK
ASSIGNED TO EXAMINER
19/11/2018
DOCK
ASSIGNED TO EXAMINER
08/11/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
27/07/2018
NWAP
NEW APPLICATION ENTERED
26/07/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ACTIMED THERAPEUTICS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.